Common side effects of imatinib and how to deal with them

Imatinib/Gleevec (Imatinib), as a molecular targeted drug, has better overall tolerance than chemotherapy drugs. However, a variety of systemic side effects may still occur during the long-term treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors and other diseases. The most common ones include edema, muscle spasm, nausea, rash, and abnormal liver function. Most of these reactions are within the controllable range and require regular monitoring and intervention based on individual conditions.

Facial and lower limb edema is one of the most common adverse reactions of imatinib, and its mechanism is related to changes in vascular permeability. Mild edema can be relieved by reducing sodium intake, appropriate diuresis, and strengthening lower limb elevation; if moderate to severe edema affects daily life, it is necessary to evaluate whether to reduce the dosage or temporarily discontinue the drug. Some patients also report muscle or joint pain, which is usually relieved by calcium and magnesium supplements or over-the-counter pain relievers.

Gastrointestinal symptoms such as nausea, diarrhea, and bloating are also common side effects. Patients are advised to take the medication after meals or with light food to reduce stomach irritation. In addition, regular monitoring of liver enzyme indicators is particularly critical, as imatinib may cause abnormal liver function, especially when used in combination with other drugs. If jaundice or transaminase significantly increases, the medication should be suspended immediately and liver-protective treatment should be given. After the indicators recover, the dosage should be resumed cautiously under the guidance of a doctor.

Skin reactions such as mild rashes can be relieved with antihistamines or topical corticosteroids; severe allergic reactions should be discontinued immediately and seek medical attention. Some patients may experience a decrease in bone density after taking imatinib for a long time. Therefore, bone metabolism indicators need to be evaluated regularly and vitamin D and calcium supplements are required. In addition, if individual patients show signs of cardiotoxicity, such as palpitations or QT interval prolongation, they should also be taken seriously and undergo electrocardiographic monitoring.

In general, although the side effects of imatinib cannot be ignored, most of them can be effectively managed under guidance. Standardized follow-up, early intervention and personalized dose adjustment together form the core of the safe medication system of imatinib.

Reference materials:https://www.gleevec.com/